Bavarian Nordic
Financials
Estimates*
| DKK | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.9b | 1.9b | 3.2b | 7.1b | 5.8b | 6.2b | 6.2b |
| % growth | 180 % | 2 % | 66 % | 124 % | (18 %) | 7 % | 1 % |
| EBITDA | 810m | 125m | 395m | 2.7b | 1.8b | 2.6b | 2.8b |
| % EBITDA margin | 44 % | 7 % | 13 % | 38 % | 31 % | 42 % | 44 % |
| Profit | 278m | (465m) | (347m) | 1.5b | 1.2b | 1.8b | 1.8b |
| % profit margin | 15 % | (24 %) | (11 %) | 21 % | 21 % | 29 % | 29 % |
| EV / revenue | 5.2x | 8.5x | 4.2x | 1.7x | 3.5x | 2.8x | 2.4x |
| EV / EBITDA | 12.0x | 129.3x | 33.7x | 4.5x | 11.2x | 6.7x | 5.4x |
| R&D budget | 341m | 399m | 1.2b | 2.2b | - | - | - |
| R&D % of revenue | 18 % | 21 % | 38 % | 32 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
* | N/A | Grant | |
€50.0m | Post IPO Debt | ||
* | N/A | $100m | SPAC Private Placement |
* | N/A | DKK1.1b | Post IPO Equity |
| Total Funding | €90.9m | ||
Recent News about Bavarian Nordic
EditBavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company operates in the global healthcare market, targeting both public health institutions and private healthcare providers. Bavarian Nordic's business model revolves around leveraging cutting-edge biotechnological research to create effective treatments and preventive measures against life-threatening diseases. Revenue is generated through the sale of proprietary vaccines and immunotherapies, as well as through strategic partnerships and licensing agreements. The company has achieved significant milestones, including European marketing authorization for its Ebola vaccine and a licensing agreement for a COVID-19 vaccine. Bavarian Nordic is committed to enhancing global health by reducing the risk of infectious diseases and improving cancer treatment outcomes.
Keywords: biotechnology, cancer immunotherapy, vaccines, infectious diseases, global health, healthcare market, biotechnological research, public health, private healthcare, strategic partnerships.
